Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report

Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter’s high toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Bou Zerdan, Maroun, Hamouche, Ramzi, Bouferraa, Youssef, Chouairy, Camil, Gholam, Dany
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247284/
https://www.ncbi.nlm.nih.gov/pubmed/35783669
http://dx.doi.org/10.1177/2050313X221106987
_version_ 1784739126777479168
author Bou Zerdan, Maroun
Hamouche, Ramzi
Bouferraa, Youssef
Chouairy, Camil
Gholam, Dany
author_facet Bou Zerdan, Maroun
Hamouche, Ramzi
Bouferraa, Youssef
Chouairy, Camil
Gholam, Dany
author_sort Bou Zerdan, Maroun
collection PubMed
description Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter’s high toxicity profile new treatment options are being explored. In this case report, we describe a case of a patient with poorly differentiated neuroendocrine carcinoma of unknown primary treated with compassionate oral everolimus after his refusal of intravenous chemotherapy.
format Online
Article
Text
id pubmed-9247284
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-92472842022-07-02 Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report Bou Zerdan, Maroun Hamouche, Ramzi Bouferraa, Youssef Chouairy, Camil Gholam, Dany SAGE Open Med Case Rep Case Report Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter’s high toxicity profile new treatment options are being explored. In this case report, we describe a case of a patient with poorly differentiated neuroendocrine carcinoma of unknown primary treated with compassionate oral everolimus after his refusal of intravenous chemotherapy. SAGE Publications 2022-06-24 /pmc/articles/PMC9247284/ /pubmed/35783669 http://dx.doi.org/10.1177/2050313X221106987 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Bou Zerdan, Maroun
Hamouche, Ramzi
Bouferraa, Youssef
Chouairy, Camil
Gholam, Dany
Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
title Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
title_full Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
title_fullStr Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
title_full_unstemmed Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
title_short Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
title_sort everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247284/
https://www.ncbi.nlm.nih.gov/pubmed/35783669
http://dx.doi.org/10.1177/2050313X221106987
work_keys_str_mv AT bouzerdanmaroun everolimusinpoorlydifferentiatedneuroendocrinecarcinomaofunknownprimaryacasereport
AT hamoucheramzi everolimusinpoorlydifferentiatedneuroendocrinecarcinomaofunknownprimaryacasereport
AT bouferraayoussef everolimusinpoorlydifferentiatedneuroendocrinecarcinomaofunknownprimaryacasereport
AT chouairycamil everolimusinpoorlydifferentiatedneuroendocrinecarcinomaofunknownprimaryacasereport
AT gholamdany everolimusinpoorlydifferentiatedneuroendocrinecarcinomaofunknownprimaryacasereport

Ejemplares similares